Targeting CHEK1: Ginsenosides-Rh2 and Cu2O@G-Rh2 nanoparticles in thyroid cancer
Cell Biology and Toxicology · 2025
DOI: 10.1007/s10565-024-09961-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biology and Toxicology, 2025. Verfasst von Lidong Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Ginsenosides, Nanoparticles, Checkpoint Kinase 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Basic Scientific Research Projects of Liaoning Provincial Education Department, the 345 Talent Project of Shengjing Hospital of China Medical University.
Abstract (Originalsprache)
Thyroid cancer (THCA) is an increasingly common malignant tumor of the endocrine system, with its incidence rising steadily in recent years. For patients who experience recurrence or metastasis, treatment options are relatively limited, and the prognosis is poor. Therefore, exploring new therapeutic strategies has become particularly urgent. This study confirmed that effective suppression of THCA cell proliferation and stimulation of apoptosis can be achieved through the application of Ginsenosides-Rh2. Through network pharmacology screening, the molecular target of Ginsenosides-Rh2 in THCA was identified as CHEK1, and its inhibitory effect was confirmed by downregulating CHEK1 protein expression. Furthermore, demonstrations conducted both in vitro and in vivo showcased that delivering Ginsenosides-Rh2 using nanoparticle carriers significantly reduced cell viability by approximately 50%, regulated DNA damage levels, apoptosis-related protein expression, and cell cycle control. The IC50 of the nanoparticle formulation was determined (B-CPAP IC50 = 88.24 μM), TPC IC50 = 79.52 μM). This study confirmed that Cu2O@G-Rh2 is effective in suppressing tumors and exhibits a significant inhibitory effect on tumor recurrence and metastasis while maintaining good safety. Cu2O@G-Rh2 nanoparticles possess excellent stability and anti-tumor efficacy. This research offers new perspectives for the treatment of THCA and demonstrates potential clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China.
- Department of Ultrasound, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, 110004, People's Republic of China.
- Department of Ultrasound, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, 110004, People's Republic of China. zhanghao@sj-hospital.org.
- Department of Radiology, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, 110004, Liaoning Province, China. zhaopf@cmu.edu.cn.
Förderung
- Basic Scientific Research Projects of Liaoning Provincial Education Department
- the 345 Talent Project of Shengjing Hospital of China Medical University
Zitieren
APA
Wang, L., Wu, X., Wang, X., Dong, M., Zhang, H., & Zhao, P. (2025). Targeting CHEK1: Ginsenosides-Rh2 and Cu2O@G-Rh2 nanoparticles in thyroid cancer. Cell Biology and Toxicology. https://doi.org/10.1007/s10565-024-09961-7
Vancouver
Wang L, Wu X, Wang X, Dong M, Zhang H, Zhao P. Targeting CHEK1: Ginsenosides-Rh2 and Cu2O@G-Rh2 nanoparticles in thyroid cancer. Cell Biology and Toxicology. 2025. doi:10.1007/s10565-024-09961-7
BibTeX
@article{Wang2025,
author = {Wang, Lidong and Wu, Xin and Wang, XinLu and Dong, Meng and Zhang, Hao and Zhao, Pengfei},
title = {Targeting CHEK1: Ginsenosides-Rh2 and Cu2O@G-Rh2 nanoparticles in thyroid cancer},
journal = {Cell Biology and Toxicology},
year = {2025},
doi = {10.1007/s10565-024-09961-7}
}
EUVIMED